Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience
- PMID: 24849823
- DOI: 10.1097/01.tp.0000446268.26771.59
Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience
Abstract
In Asia, evidence-based guidelines for the management of hepatocellular carcinoma (HCC) have evolved, including the option of liver transplantation. Because of the continuing serious organ shortage, however, living donor liver transplantation (LDLT) remains the mainstream in Japan. Unlike deceased donor transplantation, living donor transplantation is not always limited by the restrictions imposed by the nationwide organ allocation system. The decision for transplantation may depend on institutional or case-by-case considerations, balancing the will of the donor, the operative risk, and the overall survival benefit. Cumulative data from the Japanese national multicenter registry analysis as well as individual center experiences suggest further expanding the criteria for LDLT for HCC from the Milan criteria is feasible with acceptable outcomes.
Similar articles
-
Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.Transplantation. 2014 Apr 27;97 Suppl 8:S20-3. doi: 10.1097/01.tp.0000446269.20934.d3. Transplantation. 2014. PMID: 24849825
-
Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience.Oncology. 2011;81 Suppl 1:111-5. doi: 10.1159/000333270. Epub 2011 Dec 22. Oncology. 2011. PMID: 22212944 Review.
-
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.Dig Dis. 2007;25(4):310-2. doi: 10.1159/000106910. Dig Dis. 2007. PMID: 17960065
-
Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years.HPB (Oxford). 2017 Dec;19(12):1082-1090. doi: 10.1016/j.hpb.2017.08.004. Epub 2017 Sep 7. HPB (Oxford). 2017. PMID: 28888776
-
Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?Liver Transpl. 2011 Oct;17 Suppl 2:S133-8. doi: 10.1002/lt.22348. Liver Transpl. 2011. PMID: 21634006 Review. No abstract available.
Cited by
-
Indications for living donor liver transplantation in patients with hepatocellular carcinoma.Hepatobiliary Surg Nutr. 2016 Oct;5(5):429-432. doi: 10.21037/hbsn.2016.09.01. Hepatobiliary Surg Nutr. 2016. PMID: 27826558 Free PMC article.
-
Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience.Ann Surg Treat Res. 2018 Nov;95(5):267-277. doi: 10.4174/astr.2018.95.5.267. Epub 2018 Oct 25. Ann Surg Treat Res. 2018. PMID: 30402445 Free PMC article.
-
Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study.Front Oncol. 2020 Dec 7;10:562103. doi: 10.3389/fonc.2020.562103. eCollection 2020. Front Oncol. 2020. PMID: 33365268 Free PMC article.
-
Liver transplantation for advanced hepatocellular carcinoma.Clin Mol Hepatol. 2016 Sep;22(3):309-318. doi: 10.3350/cmh.2016.0042. Epub 2016 Sep 25. Clin Mol Hepatol. 2016. PMID: 27729631 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical